Ordering BPC-157 for a research project comes down to a few practical tasks: choosing the right vial size, getting batch documentation that matches the material you receive, and allowing enough time for delivery before your study starts. The scientific interest behind the purchase deserves the same care, because the evidence for this peptide is much stronger in animals than in people.

The benefits of using BPC-157 come almost entirely from preclinical studies, which report faster repair of tendon, ligament, muscle and gut lining in animal models; human evidence is limited to a handful of small, low-quality studies. That gap shapes how you should plan a protocol and what you should ask a supplier for.
Timing needs a similar reality check. Dispatch within 48 hours describes when a parcel leaves the warehouse, and courier transit comes after that. If you have a deadline, check stock, order cut-off times and courier coverage for your postcode before you commit. When you are ready, our BPC-157 product pages list the batch details you will want to compare against your own requirements.
What Does Research Suggest About Tissue Repair and Gut Health?
Most published work points to faster healing in rats and other animals, with effects seen in tendons, ligaments, muscle, nerves, skin wounds and the digestive tract. Researchers link these results to new blood vessel growth, changes in growth factor signalling and lower inflammatory markers. Human trials remain small and uncontrolled.
What Is BPC-157, and Why Is It Studied?
BPC-157 stands for body protection compound-157. It is a synthetic peptide made of 15 amino acids, so scientists also call it a pentadecapeptide. Its sequence comes from a protein fragment found in human gastric juice, and it was first described in the early 1990s.
Early work focused on stomach protection. The peptide stays stable in gastric juice, which made it interesting for ulcer research. Over three decades, preclinical studies widened the scope to the liver, pancreas, heart, nerves and musculoskeletal tissue.
A 2024 systematic review in orthopaedic sports medicine found 36 relevant studies. Of those, 35 were preclinical and just one involved patients. That ratio is the clearest summary of where the field stands on proposed BPC-157 benefits.
Tendon, Ligament and Muscle Repair in Preclinical Studies
Animal models give the most consistent musculoskeletal findings. Published rat studies report:
- Tendon: faster healing of cut Achilles tendons, plus more growth, survival and migration of tendon cells in lab dishes.
- Ligament: better structural and functional healing of injured knee ligaments.
- Muscle: improved recovery of cut quadriceps muscle, measured by function and tissue structure.
- Bone and nerve: better healing in fracture and nerve injury models, including spinal cord injury in rats.
These results describe tissue healing in controlled injury models. They do not show that muscle recovery or injury recovery follows the same pattern in people. Most of this work also comes from a small number of research groups, which reviewers flag as a reason for caution.
Gut Lining and Inflammatory Bowel Disease Models
Gut research is where BPC-157 started. Rat studies show protection against stomach and duodenal lesions caused by stress, alcohol and anti-inflammatory drugs. One study reported that BPC-157 helped stabilise intestinal permeability after NSAID damage, the process popularly called “leaky gut”.
The peptide was developed under the code PL 14736 for inflammatory bowel disease, and early clinical trials in ulcerative colitis were registered. No approved treatment came out of that work. For now, gut-lining findings stay in the animal and early-trial category.
How Might Angiogenesis and Growth Factors Contribute?
Angiogenesis means the growth of new blood vessels. In wound and sponge models, BPC-157 showed a stronger angiogenic effect than standard anti-ulcer agents. Markers such as VEGF rose early in healing and dropped later.
The systematic review above also notes higher growth hormone receptor expression and lower inflammatory cytokines in preclinical work. Better blood supply would help explain why tendons and ligaments, which have poor circulation, respond in animal models. Treat this as a working theory: the exact mechanism has not been confirmed in human tissue.
What Should Laboratory Buyers Check Before Ordering?
Start with the batch documentation, then match the vial size and form to your protocol. A purity figure on its own leaves several questions open, including identity, actual content per vial and contamination. Each needs its own check.
Choosing Between 5mg and 10mg Research Quantities
We list BPC-157 in 5mg and 10mg vials, plus a combined BPC 5mg and TB-500 10mg option. Pick the size by working back from your study design: number of samples, planned concentrations and how many repeat runs you need.
A few practical points help:
- Smaller vials suit pilot work, where you open fewer units and waste less once reconstituted.
- Larger vials reduce batch switching across a longer study, which keeps results comparable.
- Ordering everything from one batch number makes your COA cover the whole project.
What Can a Batch COA and HPLC Results Tell You?
A certificate of analysis (COA) reports the tests run on a specific batch. Every batch we sell comes with a COA, and our compounds are HPLC verified with an advertised purity grade of 99%+.
HPLC (high-performance liquid chromatography) separates a sample into its parts. The main peak shows the target compound, and the smaller peaks show impurities. When you read a COA, check:
- The batch or lot number matches the label on your vial.
- The test method and acceptance criteria are stated.
- The reported result and the test date.
- Who carried out or reviewed the testing.
Why Purity Does Not Establish Identity, Quantity or Sterility
Purity tells you what share of the sample is the main compound. It does not prove that compound is BPC-157. Identity needs a method such as mass spectrometry, which confirms the molecular weight matches the expected sequence.
Quantity is a separate question again. A 99% pure vial could still hold less than the labelled 10mg if the fill or net peptide content is off. Sterility and endotoxin levels need their own tests, and a standard purity result says nothing about either. If your protocol depends on any of these, ask for the specific data before ordering.
Confirming Product Form, Storage and Solvent Compatibility
Retailer descriptions of BPC-157 often conflict. Some list the free base and others BPC-157 acetate, a salt form with a different molecular weight. That difference affects your concentration calculations, so confirm the form on the batch COA and check it against a recognised chemical reference.
Lyophilised (freeze-dried) peptides are normally stored cold and dry, away from light. Solvent choice and stability after reconstitution depend on the exact form and your method. Use the supplier’s batch information and published references to set these, and avoid copying figures from unrelated product listings.
Where Do Safety Evidence and Research-Use Boundaries Stand?
Human safety data for BPC-157 is close to absent, and the compound is sold strictly for laboratory research. It is an experimental peptide with no approved medical use, and regulators and sports bodies treat it with caution.
What Is Known About Side Effects and Long-Term Uncertainty?
Preclinical safety studies found no adverse effects across several organ systems, and researchers could not reach a lethal dose in animals. That is useful context, but it tells us nothing firm about BPC-157 side effects in people.
A 2026 systematic review found only three small human studies with 30 participants in total. The authors rated their quality as poor and the certainty of evidence as very low. Long-term effects in humans are unknown.
Regulatory positions reflect this. The US FDA placed BPC-157 in its Category 2 list in 2023, citing safety concerns. WADA lists it as a prohibited non-approved substance. In the UK it has no marketing authorisation as a medicine, so check current MHRA guidance for your own work.
Angiogenesis and Cancer Growth: A Theoretical Concern
The same blood vessel growth that may help healing raises a question about tumours. Cancers rely on new blood supply to grow, so a compound that promotes angiogenesis could, in theory, support cancer growth.
No study has shown that BPC-157 causes or speeds up cancer. The concern is theoretical and comes from its mechanism. It remains one reason reviewers call for proper long-term safety work before any human use.
Why Oral and Injectable Claims Do Not Establish a Human Dosage
Online sellers promote oral BPC-157, BPC-157 capsules and BPC-157 injection as if each had a proven human dose. None does. Animal doses are set by body weight in rats, and they do not convert neatly to people.
Animal data suggest a half-life of under 30 minutes, with breakdown in the liver and clearance by the kidneys. Absorption from an oral product depends on the exact formulation, and no human data confirm it for any product on the market. We provide no BPC-157 dosage or administration guidance, and our products are for research use only.
How Do BPC-157 and TB-500 Differ?
TB-500 is a synthetic fragment related to thymosin beta-4, a natural protein involved in cell movement and repair. Researchers often study the two together, and the pairing is nicknamed the “wolverine stack” in peptide therapy circles.
| Feature |
BPC-157 |
TB-500 |
| Origin |
Gastric juice protein fragment |
Thymosin beta-4 fragment |
| Length |
15 amino acids |
Short active region of thymosin beta-4 |
| Main research focus |
Gut lining, tendon, ligament |
Cell migration, wound repair |
| Human evidence |
Very limited |
Very limited |
| Our vial sizes |
5mg, 10mg |
2mg, 5mg, 10mg |
Studies of BPC-157 and TB-500 together are scarce. Claims that the combination works better have no clinical support.
Match the Research Question to the Batch Documentation
The strongest case for BPC-157 sits in preclinical studies of tendon, ligament, muscle and gut repair, and human evidence is still too thin to support therapeutic claims. That makes careful sourcing the part of the work you control.
Before you order, write down what your protocol needs to know:
- Identity: request mass spectrometry data if your results depend on confirmed sequence.
- Purity: check the HPLC trace and acceptance criteria on the batch COA.
- Content: confirm net peptide amount if your concentrations must be exact.
- Form: note whether the material is free base or acetate before you calculate molarity.
- Timing: allow for dispatch plus courier transit, and check cut-offs and postcode coverage.
Our BPC-157 comes in 5mg and 10mg vials with a COA for every batch, HPLC verification and typical dispatch within 48 hours. Keep the batch number with your lab records so every result traces back to the material you tested.
Frequently Asked Questions
Are BPC-157 benefits different for men and women?
No study has compared BPC-157 benefits between men and women. Almost all the data come from animal models, and human trials are too small to show sex differences. Claims that it works differently for either sex have no published support.
Has BPC-157 been shown to provide joint pain relief in humans?
Not in any controlled trial. One retrospective study reported that 7 of 12 people with chronic knee pain described pain relief lasting over six months after a single injection, but it had no control group. A Phase II hamstring-strain trial is recruiting, with no results yet.
Does BPC-157 affect testosterone?
No published human study shows that BPC-157 changes testosterone. Preclinical work reports higher growth hormone receptor expression in tissue, which is a different pathway. Any hormonal claim goes beyond the current evidence.
Is BPC-157 hard on your liver?
Animal studies show the liver breaks down BPC-157, and preclinical safety studies reported no liver harm. Some rat models even show liver protection. No clinical safety data exist, so effects on the human liver are unknown.
Is there an established safe daily dosage of BPC-157?
No. No regulator has approved a human dose, and the few human studies are too small to define one. Our BPC-157 is sold for laboratory research only, and we give no dosing advice.
What alternatives to BPC-157 can I discuss with a healthcare provider?
A healthcare provider can talk you through licensed, evidence-based options for joint pain, tendon injuries or gut conditions. These include physiotherapy, approved medicines and specialist referral where needed. They can also explain the risks of unapproved compounds for your situation.